CAPRICOR THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CAPR$8.87-9.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years ended December 31, | ||||||
| | | 2023 | 2022 | |||
| Cash flows from operating activities: | | | | | | |
| Net loss | | $(22,287,542) | | $(29,019,532) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | ||||
| Loss on disposal of fixed assets | | | 6,041 | | | 34,266 |
| Depreciation and amortization | | 1,068,882 | | 533,131 | ||
| Stock-based compensation | | 7,392,396 | | 4,458,578 | ||
| Changes in lease liabilities | | | (24,282) | | | 161,740 |
| Changes in operating assets and liabilities: | | | ||||
| Receivables | | (9,824,413) | | (155,830) | ||
| Prepaid expenses and other current assets | | (75,884) | | 240,045 | ||
| Other assets | | — | | 7,550 | ||
| Accounts payable and accrued expenses | | | 1,388,078 | | | 1,718,312 |
| Accounts payable and accrued expenses, related party | | | (61,755) | | | (510,154) |
| Deferred revenue | | (3,178,066) | | 27,448,531 | ||
| Net cash provided by (used in) operating activities | | (25,596,545) | | 4,916,637 | ||
| | | | | | | |
| Cash flows from investing activities: | | | ||||
| Purchase of marketable securities | | (97,441,506) | | (114,218,737) | ||
| Proceeds from sales and maturities of marketable securities | | 104,597,249 | | 82,505,961 | ||
| Purchases of property and equipment | | | (1,311,660) | | | (2,000,243) |
| Payments for leasehold improvements | | (735,873) | | (1,359,488) | ||
| Net cash provided by (used in) investing activities | | 5,108,210 | | (35,072,507) | ||
| | | | | | | |
| Cash flows from financing activities: | | | ||||
| Net proceeds from sale of common stock | | 25,515,349 | | 4,803,534 | ||
| Proceeds from exercise of stock awards | | 64,601 | | 70,304 | ||
| Net cash provided by financing activities | | 25,579,950 | | 4,873,838 | ||
| | | | | | | |
| Net increase (decrease) in cash and cash equivalents | | 5,091,615 | | (25,282,032) | ||
| | | | | | | |
| Cash and cash equivalents balance at beginning of period | | 9,603,242 | | 34,885,274 | ||
| | | | | | | |
| Cash and cash equivalents balance at end of period | | $14,694,857 | | $9,603,242 | ||
| | | | | | | |
| Supplemental disclosures of cash flow information: | | | ||||
| Interest paid in cash | | $— | | $— | ||
| Income taxes paid in cash | | $— | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.